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Mass spectrometryProteome profiling is the method of choice to identify marker proteins whose expression
may be characteristic for certain diseases. The formation of such marker proteins results
from disease-related pathophysiologic processes. In healthy individuals, peripheral blood
mononuclear cells (PBMCs) circulate in a quiescent cell state monitoring potential
immune-relevant events, but have the competence to respond quickly and efficiently in
an inflammatory manner to any invasion of potential pathogens. Activation of these cells is
most plausibly accompanied by characteristic proteome alterations. Therefore we investigat-
ed untreated and inflammatory activated primary human PBMCs by proteome profiling using
a ‘top down’ 2D-PAGE approach in addition to a ‘bottom up’ LC–MS/MS-based shotgun
approach. Furthermore, we purified primary human T-cells and monocytes and
activated them separately. Comparative analysis allowed us to characterize a robust
proteome signature including NAMPT and PAI2 which indicates the activation of PBMCs.
The T-cell specific inflammation signature included IRF-4, GBP1and the previously
uncharacterized translation product of GBP5; the corresponding monocyte signature
included PDCD5, IL1RN and IL1B. The involvement of inflammatory activated PBMCs in
certain diseases as well as the responsiveness of these cells to anti-inflammatory drugs
may be evaluated by quantification of these marker proteins.
This article is part of a Special Issue entitled: Integrated omics.
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immune players and therefore involved in a large number of
diseases. In healthy individuals, these cells circulate in a
quiescent state monitoring potential immune-relevant events.
Encountering any kind of disease-related abnormalities may
elicit strong inflammatory responses in these cells which are
targeted at the elimination of potential pathogens but may also
cause severe side effects and malicious symptoms. Inflamma-
tory activation engages several biological functions such as
leukocyte migration, proliferation of T-cells, interferon re-
sponse, NF-κB signaling and regulation of cell death. Proteome
profiles characteristic for such functional cell states have not
yet been comprehensively investigated in inflammatory acti-
vated PBMCs.
Proteomics is a powerful screening technology aiming at
the high throughput analysis of complex samples mainly
using mass spectrometry [1]. Several studies have been
performed in order to analyze proteome profiles of quiescent
PBMCs, resulting in the classification of proteins according to
functional groups and cellular localization [2] or cell type
specificity [3]. PBMCs consist of several different cell types and
proteome analyses of these cells result in great complexity of
data, especially when including the consideration of different
functional states. Additionally, the heterogeneity of biological
samples andmethodological challengesmay obstruct straight
interpretation of data [4,5].
Indeed, PBMCs consist of different cell types with lympho-
cytes and monocytes as main constituents and more than two
thirds of the lymphocytes represented by T-cells. Furthermore,
each of these cells can occur at different functional states,
especially when cells from diseased persons are considered.
Activated T-cells may account for intrinsic immune response-
related tissue damage characteristic for chronic inflammation,
autoimmunity and graft versus host disease [6]. Monocytes act
as important regulators of T-cell activities. Upon encounterwith
a potential pathogen, monocytes become activated resulting in
differentiation into macrophages. Macrophages present phago-
cytized and processed material on their cell surface and thus
induce the targeted activation of T-cells. Activated T-cells in
turn may further activate endothelial cells, fibroblasts and
monocytes/macrophages thus maintaining an acute or chronic
inflammatory state [7]. Recently, differential PBMC protein
expression was shown to support the diagnosis of ulcerative
colitis and Crohn's disease [8] as well as of systemic lupus
erythematosus [9] or rheumatoid arthritis [10].
While the role of the immune system for several diseases
such as pathogen-related disorders is obvious and well under-
stood, the detailed regulatory mechanisms involved in disor-
ders such as chronic inflammatory diseases, atherosclerosis,
Alzheimer and cancer are not yet fully understood and
therefore in the focus of current research [11–14]. The proteomic
characterization of PBMCs and of functional cell states thereof
may help to indicate and assess the contribution of these cells
to certain diseases.
While current data interpretation strategies for large‐omics
data sets rather rely on network analysis [15], we seek a
systematic strategy based on the establishment of referenceproteome profiles. Especially, we focus on the characterization
of proteins specifically expressed in individual cell types at
defined functional states. We have already characterized pro-
teins specifically expressed in inflammatory activated as well
as tolerogenic primary human dendritic cells [16]. Our research
group has also been working with PBMCs focusing on oxidative
stress [17] and nutritional intervention [18].
In the present work, in order to generate further reference
proteome profiles, we focus on PBMCs which were inflamma-
tory activated in vitro with LPS (lipopolysaccharide) and PHA
(phytohaemagglutinin) and subsequently analyzed using 2D-
PAGE (‘top down’), as well as an LC–MS/MS based shotgun
approach (‘bottom up’) [19]. Proteome profiles were recorded
and compared to those of control PBMCs using the Griss
Proteomics Database Engine (GPDE), a database specifically
engineered for the identification and characterization of
marker proteins [20]. In order to relate the observed proteome
alterations to the corresponding cell type of origin, we isolated
and stimulated T-cells (with PHA) and monocytes (with LPS),
the two main cellular constituents of PBMCs, separately
before subsequent analysis. We thereby successfully identi-
fied proteins that are newly expressed or up-regulated both in
T-cells and monocytes. Additionally, we identified proteins
specifically induced in T-cells and monocytes, respectively,
upon activation. Knowledge of these marker proteins may
reveal the involvement of inflammatory-activated T-cells or
monocytes in biological samples, which may strongly support
the interpretation of more complex clinical proteomics data
whenever inflammatory activated PBMCs may be involved.2. Material and methods
2.1. Blood samples
PBMCs of six individuals were isolated. From each donation we
created four aliquots. Two were used for metabolic labeling
(untreatedand treated) and subsequently analyzed by 2D-PAGE.
The other two aliquots were fractionated and further processed
for shotgun analysis. Per group, fractionation resulted in six
cytoplasmic fractions. Three of them were analyzed twice,
resulting in a total of nine shotgun analyses. Five nuclear
extracts were successfully isolated and analyzed, while only
two secretomes were successfully analyzed. T-cells and mono-
cytes were isolated from four independent blood donations and
the corresponding cytoplasmic aliquots were processed for
shotgun analysis. In case of two T-cell preparations, aliquots
were treated in two different ways (PHA and ionomycin/PMA,
respectively). The corresponding PRIDE-experiments are listed
in Supplementary Table 2. We have not generated PRIDE-files
for the spots identified in 2D-gels.
2.2. Isolation and cultivation of PBMCs
PBMCs were isolated from fresh blood (blood samples from
volunteers) of healthy donors with written consent of each
donor and the approval of the Austrian Ethics committee
(no. 297/2011). For the isolation of PBMCs, 50 ml full blood were
diluted with RPMI1640 medium (Gibco Ltd., Paisley, Scotland)
and supplemented with 2 mM L-glutamine, 100U/ml penicillin,
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1000U heparin (EBEWE Pharma, Unterach, Austria). 35 ml of
themixture were then carefully overlaid above Ficoll-Paque (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden) and centrifuged
at 500 g for 30 min at 14 °C. PBMCs were collected from the
interphase and were then either re-seeded in diluted
autologous plasma or, if used for subsequent cell purifica-
tion, washed with RPMI Heparin medium and MACS buffer
(PBS 1% Human Serum Albumin (Aventis Behring, Vienna,
Austria)/5 mM EDTA (Gibco Ltd., Paisley, Scotland) and counted
[21,22].
2.3. Monocyte and T cell separation
T-cells and monocytes were separated by magnetic sorting
using the MACS technique (Miltenyi Biotec, Bergisch Gladbach,
Germany), including the use of MACS buffer, Streptavidin
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany), CS
columns (Miltenyi Biotec) and the VarioMACS separator. T-cells
were obtained by negative selection, which was done by
depletion of the PBMCs flowtrough from non-T-cells using an
antibody mix containing anti-CD14 (MEM 18) for monocytes,
anti-CD16 (3G8) for granulocytes and NK‐cells, anti-CD19 for B
cells (BU 12) and anti-CD33 (4D3) for monocytes, thrombocytes
and myeloid progenitors, all at concentrations of 10 μg/ml. For
monocytes up to 1×109 cells were positively enriched by
incubating the PBMCs with 15 μg/ml of biotinylated anti-CD14
(VIM13, MEM 18) to label the monocytes [23].
2.4. FACS analysis of purified T-cells and monocytes
This method was applied to verify the purity of isolated T-cells
and monocytes. The cell suspension (5×105 cells/assay) was
resuspended in 50 μl Beriglobin (CSL Behring) and kept for 10 min
on ice. 20 μl of the following PE or FITC-conjugated mouse
antibodies were used at a concentration of 20 μg/ml each: VIAP
(clone 2D5), CD3 (UCHT1) and CD4 (vit4)/CD8 (Vit8) provided from
the Institute of Immunology from Otto Majdic; CD45 (HI30)/CD14
(TüK4), CD3 (S4.1)/SJ25-C1, CD3 (S4.1)/HLA-DR (Tü36) and CD56
(MEM188) from Caltag. Antibodies were prepared in Micronic-
tubes and 50 μl of the cell suspension was added, mixed
and incubated for 30 min at 4 °C. Dead cells were labeled by
addition of ethidiumbromide or propidiumiodide (1:100).
The tubes were kept on ice until they were analyzed by
flow-cytometry. Purity of monocytes was found to be above
95%, for T-cells above 98% (see Supplementary Fig. 1). In
case of monocytes, we did not collect sufficient cell amounts to
allow the analysis of nuclear extracts and secreted protein
fractions.
2.5. 35S-metabolic labeling for measuring of protein
synthesis
After isolation PBMCs were reseeded in diluted plasma of
the donor in the presence of 35S-labeled methionine and
cysteine (Trans35label, Biomedica, MP Biomedicals) for 6 h
at 37 °C. The induction of new protein synthesis which is
observed by autoradiography is highest within the first few
hours after stimulation [24], therefore here we chose 6 h
labeling time.2.6. Inflammatory stimulation
For activation of PBMCs for 2D-PAGE, cells were resuspended
in blood plasma and treated with 1 μg/ml lipopolysaccharide
(LPS, Sigma-Aldrich) [25], inducing an immune response in
monocytes via the toll-like pathway (Myd88) [26–28], and 5 μg/ml
phytohaemagglutinin (PHA, Biochrom) [29], a lectin acting
mitogenic in T-cells causing proliferative cell division [30],
for 6 h at 37 °C. For shotgun analysis, PBMCs were diluted in
RPMI medium to 1×106 cells/ml and treated as above with a
combination of LPS and PHA (same concentrations) for 24 h
in order to provide the cells sufficient time to cumulate
newly synthesized proteins [31]. Isolated monocytes or
T-cells were treated with 1 μg/ml LPS or 5 μg/ml PHA for
24 h, respectively. Alternatively T-cells were activated by 1 μM
ionomycin/100nM PMA (phorbol 12-myristate 13-acetate) for
24 h [32–34].
2.7. Sub-cellular fractionation
The in vitro treated cells were grown in culture medium for
16 h and further in serum-free medium for 8 h (together 24 h)
to collect the secretome. To minimize unspecific effects on
cells due to the in vitro culturing conditions we obtained
controls either by directly processing isolated PBMCs or after
8 h of incubation time.
2.7.1. Secretome protein isolation
After that period of time the supernatant was sterile-filtered
through a 0.2 μm filter and precipitated overnight by addition
of ethanol tempered to −20 °C.
2.7.2. Cytoplasmic protein isolation
The isolation of cytoplasmic proteins was performed as
described by Gundacker et al. [35]. During all steps samples
were kept on ice. Cells were lysed in isotonic lysis buffer
(10 mM HEPES/NaOH, pH 7.4, 0.25 M sucrose, 10 mM NaCl,
3 mM MgCl2, 0.5% Triton X-100) supplemented with protease
inhibitors (pepstatin, leupeptin and aprotinin, each at 1 μg/ml;
1 mM PMSF) and pressed through a 23 g syringe to induce cell
lysis. The cytoplasmic fraction was separated from nuclei by
centrifugation at 3500 rpm and 4 °C for 5 min and precipitated
overnight by addition of ethanol tempered to −20 °C.
2.7.3. Nuclear fraction protein isolation
Thenuclear pellets swelled up in extraction buffer (500 mMNaCl)
for 10 min followed by a 1:10 dilution in NP-40 buffer for 15 min,
to reduce the NaCl concentration. The nuclear protein fraction
was separated from debris by centrifugation at 3500 rpm
and 4 °C for 5 min and precipitated overnight by addition of
ethanol tempered to −20 °C. Afterwards, all protein samples
were dissolved in sample buffer (7.5 M urea, 1.5 M thiourea,
4% CHAPS, 0.05% SDS, 100 mM DDT).
2.8. 2D-PAGE (‘top down’)
Cytoplasmic proteins were loaded by passive rehydration on
IPG strips pH 5–8, 17 cm (BioRad, Hercules, CA) at room
temperature. Isoelectric focusing (IEF) was performed in a
stepwise fashion (1 h 0–500 V linear; 5 h 500 V; 5 h 500–3500 V
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100 mM DTT and 2.5% iodacetamide according to the in-
structions of the manufacturer (BioRad). For SDS-PAGE the
Protean II xi electrophoresis system (BioRad) was used. IPG
stripswere placed on top of 1.5 mm12%polyacrylamide slab gels
and overlaidwith 0.5% low-melting agarose with bromophenol
blue. After electrophoresis, gels were stained with a 400 nM
solution of Ruthenium II tris (bathophenanthroline disulfonate)
(RuBPS) as described before [36]. For this purpose the gels were
fixated in 50% methanol/7% acetic acid overnight, next day
washed two times for 30 min with 20%methanol, then stained
for 6 h with 400 nM RuBPS, and destained overnight in 15%
methanol/7% acetic acid. Fluorography scanning was again
performed with the FluorImager 595 at a resolution of 100 μm
[37]. After scanning the fluorescence of the gels, the gels were
dried for subsequent autoradiography. Dried gels were inserted
into cassettes including a phosphor screen as detector for
ß-radiation of the 35S labeled proteins. These phosphor screens
were scanned with the PhosphorImager SI MAC (Molecular
Dynamics) with 100 microns. Gels were warped to a reference
gel with the TT900 S2S software (version 2006.0.2389, Nonlinear
dynamics, Carlsbad, CA) and evaluated with the Progenesis
software PG200 (version 2006, Nonlinear) using the “same spot”
algorithm. Only protein spots which displayed a more than
two-fold increase on average of the corresponding normalized
integrated spot intensity were considered as differently regu-
lated and were further analyzed by mass spectrometry.
2.9. 1D-PAGE for subsequent shotgun analysis (‘bottom up’)
Protein fractions (supernatant, cytoplasm and nuclear ex-
tracts) were loaded on 12% polyacrylamid gels, electrophore-
sis was performed until complete separation of a pre-stained
molecular marker (Dual Color, Biorad, Hercules, CA) was
visible. After fixation with 50% methanol/10% acetic acid and
subsequent silver staining, gel lanes were cut out of the gel
and digested with trypsin as described below.
2.10. MS-compatible silver staining procedure
SDS-PAGE gels were fixed with 50% methanol, washed and
sensitized with 0.02% Na2S2O3. The gels were stained with
0.1% AgNO3 ice cold for 20 min, rinsed with bi-distilled water
and subsequently developed with 3% Na2CO3/0.05% formal-
dehyde as previously described [38].
2.11. Protein digestion with trypsin
Spots were cut out from 2D-gels. SDS-gels were cut into slices.
After destaining, reduction with DTT and alkylation with
iodacetamide, proteins were digested with trypsin (sequencing
grade, Roche) at 37 °C overnight as described before [39]. After
elution, the peptides were forwarded to LC–MS/MS analysis.
2.12. Mass spectrometry analysis
For the identification of isolated 2D spots, the corresponding
peptides were loaded on a Zorbax 300SB-C8 (5 μm, 0.3 mm,
5 mm) column and separated by nanoflow LC (1100 Series LC
system, Agilent, Palo Alto, CA) with a Zorbax 300SB-C18 (5 μm,75 mm) columnat a flow rate of 250 nl/minusing a gradient from
0.2% formic acid and3%acetonitrile (ACN) to0.2% formic acid and
45% ACN over 12 min. In case of shotgun analysis, peptides were
separated by nanoflow LC (1100 Series LC system, Agilent, Palo
Alto, CA)using theHPLC-Chip technology (Agilent) equippedwith
a 40 nl Zorbax 300SB-C18 trapping columnanda 75 μm×150 mm
Zorbax 300SB-C18 separation columnat a flow rate of 400 nl/min,
using a gradient from0.2% formic acid and3%ACN to 0.2% formic
acid and 50% ACN for over 60 min. Peptide identification was
accomplished by MS/MS fragmentation analysis with an iontrap
mass spectrometer (XCT-Ultra, Agilent) equipped with an or-
thogonal nanospray ion source. The MS/MS data analysis,
including peak list-generation and spectrum identification, was
done using the Spectrum Mill MS Proteomics Workbench
software (Version A.03.03, Agilent) allowing for two missed
cleavages and searched against the SwissProt/UniProtKB protein
database for human proteins (Version 12/2010 containing 20,328
entries) allowing for precursormassdeviationof 1.5 Da, aproduct
mass tolerance of 0.7 Daandaminimummatchedpeak intensity
(%SPI) of 70%. Due to previous chemicalmodification, carbamido-
methylation of cysteineswas set as fixedmodification. Oxidation
of methionine was the only post-translational modifications
consideredhere. The apparent positivematches foundwithin the
search results for peptides having a SpectrumMill peptide score
higher than 13 when using the corresponding reversed database
compared to the true database were consistenly less than 1%
(documented in the PRIDE XML files). Peptides scoring between 9
and 13 were included only if precursor m/z value, retention time
and MS2 pattern were found similarly in at least one of our
previous experiments and the peptidewas thereby scoring above
13. With respect to protein inference, we chose the smallest
number of proteins required to explain all observed peptides as
described for ProteinProphet [40]. As our protein identification
algorithm includes manual selection, we cannot calculate an
exact false discovery rate. All identification details includingMS2
spectra are fully documented in the PRIDE-XML files available at
www.ebi.ac.uk/pride (experiments 22162–22200, 26890–26904,
Table S2).
2.13. Data evaluation of shotgun analyses
The PRIDE-XML files were loaded into a local version of the
GPDE, the software can be downloaded freely from http://
sourceforge.net/projects/gpde/. For uploading the files, the
parameters “species”, “tissue”, “cell type” and “cell state” as
well as “sub-cellular fraction” were set accordingly. Data
replicates become assembled as described [20], the emPAI
(exponentially modified protein abundance index) values
were calculated according to Ishihama et al. [41] using the
“Data Analysis” tool. The cell symbols were obtained using the
“Protein Expression” tool. In Figs. 3 and 4, snapshots of the
database output screens are shown.3. Results
3.1. 2D-PAGE of control and LPS/PHA-treated PBMCs
Primary cells present a significant challenge to proteome
research because of their intrinsic heterogeneity, instability
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applied strict standard operating procedures to minimize the
differences between the working procedures. PBMCs from
six individual donors were isolated under sterile condi-
tions, transferred back into plasma of the corresponding
donor and metabolically labeled for 6 h by the addition of
35S-methionine/cysteine. One aliquot was treated with LPS,
an activator of monocytes, and PHA, an activator of T-cells
(see Section 2). 2D-PAGE separation of cytoplasmic proteins,
fluorescence detection and subsequent autoradiography allowed
us to record a marked increase in protein synthesis in the
stimulated cells (Fig. 1). The comparison of the activated cells
with the untreated controls considering both fluorescence and
autoradiographic protein detection identified several proteins to
be specifically induced as exemplified in more detail for IFIT-2
(Fig. 2). Selected protein spots of corresponding unlabeled cell
preparationswere excised, digestedwith trypsin and analyzed by
mass spectrometry. 14 proteins displayed a more than two-fold
increase on average of the corresponding normalized integrated
spot intensity and were identified using MS as indicated in Fig. 1.
Although the autoradiographic spot patterns of the individual
donors showed some variations, the inflammation-induced
alterations were of very high conformity (Fig. S1).
3.2. Shotgun analysis of control and LPS/PHA-treated
PBMCs
Additionally, unlabeled cell aliquots of similar experiments
were analyzed using shotgun proteomics. Eight hours afterFig. 1 – Comparison of the cytoplasmic protein fractions from un
detection and autoradiography from 2D gels. Cytoplasmic protei
inflammatory activated PBMCs (Act) were separated by 2D-PAGE,
to phosphor-screens. The first row (Fl) features the fluorescence
(AR) images. The fluorescence images provide qualitative and
composition of the PBMCs. The autoradiographs display prote
UniProtKB/SwissProt accession numbers indicate proteins wh
upon inflammatory activation.treatment, when inflammation-induced protein synthesis was
apparently up-regulated most significantly (Fig. 2), shotgun
analysis did not reveal several of the alterations observed in the
2D gels (data not shown). However, after 24 h of treatment,
most of the proteins found induced by means of 2D-PAGE were
as well identified by shotgun proteomics. Shotgun proteomics
requires some threshold protein amounts which may re-
quire the accumulation of several hours of successful protein
synthesis. As specifically detecting protein synthesis, auto-
radiography may therefore provide more contrasting results
than determination of protein amounts (Fig. 2). Furthermore,
we observed that in vitro culturing of PBMCs for several hours
without treatment was sufficient to induce some inflamma-
tory activation of cells. The immune cells may easily re-
cognize the environmental change accompanying blood
processing and respond to it. Consequently, we processed
untreated cells directly after isolation. Then, cytoplasmic,
nuclear and secreted protein fractions were separated by
SDS-PAGE, digested with trypsin and analyzed by mass
spectrometry as described previously [3]. For data analysis
only proteins identified with at least two distinct peptides
and in at least two independent experiments were consid-
ered. Based on these conditions, 1496 proteins were identified in
the untreated cells and 1497 proteins in the inflammatory
activated cells. 1424 proteins of these were common to both
groups (Supplementary Data Table S1). All identification details
including MS2 spectra are fully documented in the PRIDE-XML
files available at www.ebi.ac.uk/pride (experiments 22162–22200,
26890–26904, Table S2).treated and inflammatory activated PBMCs by fluorescence
ns of untreated PBMCs (Con) and, by LPS and PHA,
stained with the fluorescence dye RuBPS, dried and exposed
images, while the second row shows the autoradiography
quantitative information about the overall protein
ins newly synthesized during the labeling period.
ich were identified as specifically induced or up-regulated
Fig. 2 – Evidence for induced protein expression by 2D-PAGE. The fluorescence pattern of inflammatory activated PBMCs (B) of a
representative donor was very similar to the corresponding control (A). The newly detectable spot was identified as IFIT-2
(P09913). The corresponding autoradiograph demonstrated very high 35S incorporation of this protein (D) and absence of
detection in the control (C). Image overlays of fluorescence detection of activated (magenta) with the control (green)
demonstrate the specificity of this protein expression (E). Image overlay of autoradiography of the activated sample (green)
with the corresponding fluorescence detection (magenta) demonstrates the very high labeling of the otherwise hardly
detectable spot (F).
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shotgun analysis
18 cytoplasmic and 6 nuclear proteins were considered as
specifically expressed upon activation as they were reliably
identified by shotgun analysis with three or more distinct
peptides in at least three out of the six donors and were not
detected in the controls. The 18 cytoplasmic proteins includ-
ing corresponding gene-ontology terms [42] are listed in
Table 1. 13 of these proteins were confirmed to be induced
using 2D autoradiographs (Table 1), and only one protein
(IFIT2) was found using 2D-PAGE and remained undetectable
using shotgun analysis (Fig. 1). One of the newly inducedproteins was identified as guanylate-binding protein 5, a
UniProtKB entry listed only with “evidenced at transcriptional
level”. The corresponding mass spectrometry data are sum-
marized in Fig. 3 and clearly evidence the expression of this
protein in activated PBMCs. The specifically induced 6 nuclear
proteins were MCM7 (P33993), SATB1 (Q01826), OAS2 (P29728),
G3BP1 (Q13283), EIF2AK2 (P19525) and MCM5 (P33992).
To obtain a rough estimate of relative protein abundances, we
calculated the average emPAI values for all proteins determined
in inflammatory activated PBMCs, over all biological replicates
(Table S1). 10 cytoplasmic and 4 nuclear proteins consistently
displayed a three-fold or higher increase of the average emPAI
(Table 2) compared to controls.
Table 1 – Grouping of proteins which were specifically expressed in inflammatory activated PBMCs according to their
expression in purified and activated T-cells and monocytes. All proteins listed here were found specifically expressed in
activated PBMCs with three or more distinct peptides in at least three out of six donors and were not detected in the
controls. T-cells and monocytes, the main constituents of PBMCs were purified, activated and analyzed separately. The
induced proteins were compared to those observed in activated PBMCs. Proteins identified in both T-cells and monocytes,
in only one cell type or in none were assembled into groups. Proteins independently observed to be up-regulated when
using 2D-PAGE are indicated by “x” in the column “2D”. A selected “biological process” GO term is listed for each protein.
2D GO - biological processes
I) Proteins induced in both activated T-cells and monocytes
P08195 4F2 cell-surface antigen heavy chain x Leukocyte migration, cell growth
P05120 Plasminogen activator inhibitor 2 (PAI-2) x Anti-apoptosis
P43490 Nicotinamide phosphoribosyltransferase x Positive regulation of cell proliferation
P61289 Proteasome activator complex subunit 3 x Regulation of apoptotic process
II) Proteins induced in activated T-cells only
Q00653 Nuclear factor NF-kappa-B p100 subunit Proliferation
Q15306 Interferon regulatory factor 4 (IRF-4) x T cell activation
P32456 Interferon-induced guanylate-binding protein 2 x Interferon-gamma-mediated signaling pathway
P12004 Proliferating cell nuclear antigen (PCNA) x proliferation
P12268 Inosine-5′-monophosphate dehydrogenase 2 x GMP biosynthetic process
P80217 Interferon-induced 35 kDa protein (IFP 35) x Type I interferon-mediated signaling pathway
Q99873 Protein arginine N-methyltransferase 1 Cell surface receptor linked signaling pathway
Q96PP8 Guanylate-binding protein 5 x GTP binding
P32455 Interferon-induced guanylate-binding protein 1 Interferon-gamma-mediated signaling pathway
III) Proteins induced in activated monocytes only
O14737 Programmed cell death protein 5 Apoptotic process
P01584 Interleukin-1 beta x Positive regulation of T cell proliferation
P18510 Interleukin-1 receptor antagonist protein (IL-1ra) x Immune response
IV) Proteins induced in activated PBMCs, but not isolated cells
P20591 Interferon-induced GTP-binding protein Mx1 x Type I interferon-mediated signaling pathway
P14902 Indoleamine 2,3-dioxygenase 1 (IDO-1) Tryptophan catabolic process
156 J O U R N A L O F P R O T E O M I C S 7 6 ( 2 0 1 2 ) 1 5 0 – 1 6 23.4. Shotgun analysis of isolated T-cells and monocytes
T-cells and monocytes are well known for their distinct
functions during inflammation. We therefore tried to relate the
activation-induced proteome alterations to the corresponding
cell type of origin. T-cells andmonocytes were isolated from the
PBMCcellmixturesof four individual donors, characterizedwith
respect to cell purity by FACS analysis (Fig. S2), and treated with
PHA and LPS for 24 h, respectively. Two T-cell aliquots were
treated with Ionomycin/PMA for 24 h as an alternative to
activation with PHA, the results were largely similar to those
obtained with PHA. 16 of the 18 proteins observed to be induced
in activated PBMCs were again identified in these purified and
activated cell populations; 4 of them in both, purified and
activated T-cells and monocytes, 9 proteins were identified in
activated T-cells, 3 proteins in activated monocytes, while 2
proteins, IDO-1 andMX1, remained undetectable in the isolated
cells (Table 1). The latter two proteins were thus found induced
in the natural cell mixture only, but not in the purified cell
populations. IDO1 has been described to be induced in human
macrophages and monocyte-derived dendritic cells upon inter-
action with T-cells [43,44]. MX1 was identified in all 2D-gels and
almost all shotgun results from activated PBMCs and also in
mature dendritic cells investigated by LC–MS/MS in a previous
study [16]. The absence of MX1 expression in the LPS-treated
monocytes, whichwas independently reproduced in the 2D gels
thereof (data not shown)may indicate that the isolated cells didnot gain the full inflammatory activation state. The full
inflammation state was therefore only obtained when the
natural cell mixture of PBMCs was present during activation.
We interpret this finding as indication for cell cooperation
between different PBMCs.
Remarkably, no protein was found induced in the purified
cell populations, which has not been identified in the activated
PBMCs. These observations lead us to the classification of these
18 proteins into four groups, which we consider as functional
signatures (Table 1); group I: signature for activated leukocytes;
group II: signature for activated T-cells; group III: signature for
activated monocytes; and group IV: signature for the coopera-
tion of activated T-cells and monocytes.
3.5. Data interpretation
In this study we used a sub-cellular fractionation approach
which was shown to increase the experimental reproducibility
of proteome profiles [35]. Additionally, it supports cross-
comparisons of protein expression patterns in specific sub-
cellular compartments. We have extended our in-house devel-
oped data analysis platform, the GPDE [20], to visualize the
average protein abundance (calculated by using the average
emPAI of biological replicates) between the different cell types.
These abundancevalues are represented as colored cell symbols
for a given selection of proteins and cell types. The average
emPAI value is translated into a color code with intensities
Fig. 3 – Identification of guanylate binding protein 5 (Uniprot Q96PP8). Readouts of the GPDE are shown and suggest safe
identification of the indicated protein. Within the amino acid sequence of the protein, the identified peptides are underlined,
summing up to sequence coverage of 24.06%. The identified sequences of all present experiments are listed indicating
whether the peptide sequence is unique within the human proteome and the number of identifications within the set of data
(first peptide: identified in 8 out of nine experiments identifying Q96PP8) as well as amino acid positions within protein
sequence, scores and fractions. Below a single MS2 spectrum of the indicated peptide sequence is shown.
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by a small inner circle for the nuclear fraction, an outer circle for
the cytoplasm and an outer frame for the secretome (Fig. 4).Using this tool the specificity of functional proteome
signatures can easily be visualized. Fig. 4 shows a single
representative of each of the above described groups as well
Table 2 – Proteins specifically up-regulated in inflammatory activated PBMCs as demonstrated by shotgun proteomics. The
assessment of quantitative alterations was based on the calculation of the emPAI (exponentially modified protein
abundance index) value for a protein identification in activated versus control PBMCs.We considered the up-regulation of a
protein in activated PBMCs as relevant only if the corresponding average emPAI value exceeded three-fold the average
value of the untreated PBMCs and was increased in this way in at least three independent experiments. Pep-con and
Pep-act, number of distinct peptides identified in untreated or inflammatory activated PBMCs respectively; exp-con and
exp-act, number of experiments with a positive protein identification in control or activated PBMCs compared to the total
number of the respective experiments; emPAI-con and emPAI-act, average emPAI value determined for a protein
identification in the cytoplasmic or nuclear protein fraction of control and activated PBMCs respectively.
pep-con exp-con emPAI-con pep-act exp-act emPAI-act
Cytoplasmic proteins up-regulated
P42224 Signal transducer and activator of transcription 1-alpha/beta 2 3/9 0.044 14 6/9 0.208
P49327 Fatty acid synthase 5 3/9 0.038 28 6/9 0.159
P23381 Tryptophanyl-tRNA synthetase, cytoplasmic 4 8/9 0.121 20 8/9 0.458
P61247 40S ribosomal protein S3a 10 4/9 0.146 13 6/9 0.523
Q14152 Eukaryotic translation initiation factor 3 subunit A 15 4/9 0.031 17 5/9 0.11
P46776 60S ribosomal protein L27a 5 5/9 0.179 6 5/9 0.624
P62263 40S ribosomal protein S14 11 8/9 1.347 13 8/9 4.248
P46781 40S ribosomal protein S9 8 4/9 0.181 13 6/9 0.569
P83731 60S ribosomal protein L24 (Ribosomal protein L30) 5 1/9 0.212 5 7/9 0.664
O00571 ATP-dependent RNA helicase DDX3X 9 1/9 0.049 16 5/9 0.149
Nuclear proteins up-regulated
Q9NR30 Nucleolar RNA helicase 2 6 2/5 0.163 25 5/5 0.777
P10144 Granzyme B 1 2/5 0.145 10 4/5 0.679
Q13765 Nascent polypeptide-associated complex subunit alpha 0 0/5 0 5 5/5 0.648
Q01469 Fatty acid-binding protein, epidermal 0 0/5 0 4 3/5 0.532
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cytoplasmic part of the cell symbol representing GAPDH
(Q96PP8) is of similar intensity in all cell types shown in
Fig. 4. GAPDH can therefore be regarded as a baseline similar
to a loading control in Western experiments. GAPDH was
detected in the secretome of inflammatory activated PBMCs
but not in the secretome of untreated controls. This clearly
indicates the presence of dead cells which have released
cytoplasmic proteins into the supernatant. NAMPT (P43490) is
shown as a representative of group I: it is undetectable in the
untreated PBMCs, T-cells and monocytes but positively
identified in all inflammatory activated cells. PCNA (P12004)
is shown as a representative of group II: it is up-regulated in
activated T-cells but not identified in monocytes and dendrit-
ic cells. Remarkably, PCNA was detected in the nuclear
fraction of untreated PBMCs which is compatible with the
known sub-cellular location of this cyclin [45]. However, the
newly induced synthesis of this protein upon induction of cell
proliferation needs to take place in the cytoplasm. Indeed,
PCNA was detected in the cytoplasmic protein fraction of
activated PBMCs. IL-1beta (P01584), representative of group III,
was found to be induced in monocytes but not in T-cells.
IL-1beta was previously described to be up-regulated in
LPS-activated monocytes [46]. IDO1 (P14902) was identified in
activated PBMCs only, thus representing group IV.4. Discussion
The results of most proteome experiments are long protein
lists which may be difficult to interpret. To support biological
data interpretationwealready classified PBMC-derivedproteins
according to their cellular origin [3]. We identified proteinsspecifically occurring in single cell types as well as proteins
shared between two or more cell types, and proteins common
to many cell types [39]. Analyzing a complex biological sample
and identifying therein proteins known to be selectively ex-
pressed may thus identify the corresponding cell type in the
sample. Proteome signatures specific for cell types in a defined
functional state could further support interpretation of complex
data. In this study we therefore present reference proteome
profiles of inflammatory activated white blood cells, including
cell type-specific inflammation signatures.
PBMCs are the immediate players of inflammatory re-
sponses and mainly consist of lymphocytes and monocytes
[47–49]. B-cells are producers of specific antibodies, while
T-cells are important regulators as well as effectors of inflam-
matory processes. Monocytes are the most important partners
of lymphocytes with a complex repertoire of cellular functions
comprising phagocytosis, presentation of antigens and para-
crine regulation of inflammation. In addition to the analysis of
the bulk PBMCmixture we have included the selective analysis
of the twomost abundant constituents, i.e. purified T-cells and
monocytes. B-cells and other leukocyte subtypes which are
present in relatively much smaller amounts were not consid-
ered here.
For a robust and reliable assessment of function-related
proteome alterations we applied two different analysis strate-
gies, a ‘top down’ and ‘bottom up’ approach, in parallel [19].
2D-PAGE is a well-established ‘top town’ technology providing
accurate quantitative protein expression patterns. However,
2D-PAGE is limited with respect to the number of proteins
accessible for quantification and a rather lab intensive tech-
nique which is hard to automatize [50]. However, by the
application of metabolic labeling, a very sensitive measure for
the induction of protein synthesiswas achieved (Fig. 2). In order
Fig. 4 – Comparative analysis of protein expression across different cell types and functional cell states. Each cell symbol
represents the protein expression of a single protein for a single cell type. Average emPAI values were calculated, increased
color intensities correspond to increased emPAI values. All positive identifications were reproduced in at least three different
donors, white fields indicate negative finding in six donors. The inner circle represents identification in the nuclear extracts,
the outer circle in the cytoplasm and the outer frame in the secreted protein fraction. Five proteins were selected: 1,
interleukin-1 beta (P01584); 2, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (P04406); 3, proliferating cell nuclear
antigen (P12004); 4, indoleamine 2,3-dioxygenase 1 (IDO-1) (P14902); 5, Nicotinamide phosphoribosyltransferase (NAmPRTase)
(P43490). GAPDH may serve as a kind of loading control, the emPAI in the cytoplasm was very similar in all cells presented
here. NAmPRTase was found upregulated in T-cells as well as monocytes and monocyte-derived dendritic cells, thus
representing a member of the first group of the proteome signature. PCNA was strongly induced in T-cells only, thus
identifying activated T-cells (second group). IL-1beta, representative for group 3 was already detectable in untreated PBMCs
cultured for eight hours and strongly induced in LPS-treated monocytes and dendritic cells but not in T-cells. IDO-1 was
strongly induced in PBMCs (leukocytes) treated with LPS and PHA, but not in activated T-cells, monocytes and dendritic cells.
The ladder observation may indicate characteristic cooperation upon inflammatory activation between the cells.
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interpretation, we complemented this approach with the
‘bottom up’ shotgun approach, our second analysis strategy.
Table 1 presents the newly synthesized proteins identified
upon inflammatory activation of PBMCs using LPS and PHA.
Corresponding gene ontology terms are also listed in order to
give insights into known biological functions of the proteins. As
can be seen, all induced proteins relate to known consequences
of inflammatory activation such as leukocyte migration (4F2
cell-surface antigen heavy chain) [51], proliferation of T-cells
(PCNA) [52], regulation of cell death (Proteasome activator
complex subunit 3, Programmed cell death protein 5) [53,54],
NF-κB signaling (NF-kappa-B p100 subunit) [55] and interferon
response (interferon regulatory factor 4, interferon-induced
guanylate-binding protein 2, interferon-induced 35 kDa protein,
interferon-induced GTP-binding protein Mx1) [56–59]. As T-cells
andmonocytes have different biological tasks it is not surprising
that these cells also display different responses to activation.
T-cells induced proteins related to the induction of proliferation
(PCNA) and several interferon-responsive proteins. Monocytes,which have no capability to proliferate, rather expressed pro-
teins regulating cell death (programmed cell death protein 5) as
well as proteins acting in a paracrine fashion (IL-1beta). By
assembling these proteins according to their expression speci-
ficity we obtained inflammatory signatures of T-cells and
monocytes. Knowledge of these specifically expressed proteins
may reveal the involvement of inflammatory activated T-cells or
monocytes in biological samples, which may strongly support
the interpretation of complex clinical proteomics data when
inflammatory activated PBMCs are involved.
The application of our standard proteome analysis procedure
and data processing system enabled us to include previously
published data into the present comparative analysis. Such
cross-experimental comparisons may further support data
validation and interpretation. To give an example: some subtle
inflammatory activation of cells was evidenced in the untreated
cells kept in culture for 8 h. In vitro cultivation without any
treatment apparently induced small amounts of IL-1beta and
NAMPT, indicating activation of monocytes (Fig. 4). This is the
reason why we used directly processed cells as controls as we
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agonists but rather on the finally obtained cell states. This
observation also demonstrates the great sensitivity of the PBMCs
to cell manipulation ex vivo. Here we also present a comparison
to previously published proteome profiles of primarymonocyte-
derived dendritic cells (DCs) [16]. While none of the inflamma-
tion signature members were identified in the immature DCs,
eight members of the inflammation signatures were also
identified as up-regulated in the inflammatory activated DCs.
Remarkably, three members of group II, the signature of
activated T-cells, were identified in activated DCs. This finding
may be somewhat unexpected as dendritic cells are close
relatives tomonocytes. However, it is in line with the previously
described observation that DCs express surface markers not
found in monocytes but characteristic for T-cells during
maturation in the thymus [60]. Considering activated DCs,
which are not members of PBMCs, we found, amongst others,
interferon lambda-1 and C-X-C motif chemokine 9 [16]. These
proteins were not identified in the activated PBMCs and may
thus represent members of an inflammatory signature of DCs.
It is our aim to extend these systematic analyses of
functional signatures of different cell types eventually resulting
in signatures which are highly specific for each single cell type
and cell state. Such knowledgewould support a fully automated
assessment of biological proteome profiles with respect to the
presence of certain cells in defined cell states. Such assess-
ments could greatly support the identification or recognition of
pathophysiologic pathways in individual samples. A recent
paper presenting proteome profiles of human vulvar cancer
samples investigated characteristic features of samples derived
from patients suffering from early relapse of disease. Interest-
ingly, the proteins correlating with such unfavorable clinical
situation are all contained in our lists of proteins which were
found induced or up-regulated in inflammatory activated
PBMCs (Tables 1, 2). This finding suggests that the invasion of
inflammatory activated leukocytes may have been the charac-
teristic feature of tumor tissue derived from these early
relapsing patients. Such recognized pathophysiologic events
could then be specifically targeted by pharmacologic means.
This is exactly what we intended to achieve with our approach:
to providemeans for researchers to interpret complexdatawith
respect to functional aspects in order to create clear hypotheses
which may then become verified subsequently.5. Outlook
The assessment of cell type-specific activation states out of
a proteome profile of a complex clinical sample should
support different issues: to recognize involved pathologic
mechanisms and to assess individual variations thereof. It
may also help to monitor drug effects. It can be assumed
that drug-induced down-regulation of inflammation will be
accompanied by the down-regulation of members of the
inflammatory signatures. Monitoring the expression rate of
such proteins may therefore provide novel means in order to
assess drug effects and drug efficiency in an individualized
fashion.
Supplementary materials related to this article can be
found online at http://dx.doi.org/10.1016/j.jprot.2012.07.012.Acknowledgements
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